Lyra Therapeutics Inc (LYRA) saw downtrend of -10.39% in the recent trading with $0.24 being its most recent. The current price level -96.44% lower than the highest price of $6.79 marked by the stock while trading over the past 52-weeks, whereas it is -4.66% higher than the lowest price of $0.25 the company dropped to over past 52-weeks. The latest news story on LYRA appeared in (InvestorPlace) under the title “LYRA Stock Earnings: Lyra Therapeutics Beats EPS, Beats Revenue for Q2 2024”.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
Sponsored
Looking into the simple moving average, Lyra Therapeutics Inc (LYRA)’s stock stands at a SMA-50 of $0.2962 while that of 5-day is reading $0.2679.
Daily rise and fall of price influence many of the traders, and in order to overcome the fluctuating effect of that and to watch the stock closely, traders focus more on stock’s 200-day moving average. At various points in trading activity, investors are more likely to be making use of that measure as a strong indicator in figuring out their support and resistance levels, and LYRA’s SMA-200 as of now is $2.7533.
Do analysts rate it as a buy, sell or hold?
Irrespective of recent performance, what’s important is what the future holds. In uncertain economic times, a clear picture is difficult to get. Analysts generally have a good understanding of the market works, which gives them a leg up in making predictions. Currently, the stock has been recommended as Moderate Buy by 3 of the brokerage firms. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 2.60 for the stock.
Lyra Therapeutics Inc Earnings – What Happened With LYRA
Coming around sales and income figures on LYRA Stock Income Statement, public trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor.
LYRA – Lyra Therapeutics Inc Stock Earnings Estimates
The perspective of Lyra Therapeutics Inc (NASDAQ:LYRA)’s current quarter earnings identifies that analysts are in consensus over the estimate of -0.32 for stock’s EPS in the current quarter. Company’s EPS for the last quarter was -0.27.
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 57.21 million. LYRA does have institutional investors; and they hold 45.86% of the stock.
Lyra Therapeutics Inc – Insider Activity and Holdings
As on 2024-06-30, PERCEPTIVE ADVISORS LLC was the top most holder in Lyra Therapeutics Inc (NASDAQ:LYRA) with an ownership of 12.76 million shares of the company or 19.9302 of the stake worth $3.53 million. The filing also reveals CITADEL ADVISORS LLC as the second largest holder in the company with a control over 7.4562 of the outstanding shares. Its stake is worth $1.32 million for having 4.77 million shares in hand.
BLACKROCK INC. also came holding a key position in the company during the recent quarter and it now holds 4.4211 of the outstanding shares. With this there are now 73.0 institutions which have possession in LYRA’s shares.
Currently, the stock has been recommended as Moderate Buy by 3 of the brokerage firms. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 2.60 for the stock.
The liquidity is a key characteristic of any stock and is the main point of focus of both short-term as well as long term investors before start trading into a stock. In recently reported quarter, Lyra Therapeutics Inc has a debt to equity ratio of 1.19.
Technical Analysis of Lyra Therapeutics Inc (NASDAQ:LYRA) stock
To comprehend better with the trade moves and investors’ behavior, exploring the short, medium and long term technical indicators along with average volume of a stock is an effective way to make use of. When looking into those indicators for Lyra Therapeutics Inc (LYRA), we notice that the stock’s 20-day average volume is at 648,440 shares and 100% of short term indicators are suggesting the stock as Sell. Medium term indicators at an average of 100% are spotting the stock at Sell with its 50-day average volume of 890,328 shares. And to end, LYRA’s 100-day average volume is 2,846,512 shares with 100% of the long-term indicators pointing towards Sell for the stock.
